A study has found that a class of drugs known as MDM2 inhibitors may have the potential to help patients with ocular inflammation uveitis, a serious condition that affects the eyes. To read about this study in more detail, you can view the source news release at the University of North Texas Health Science Center’s website by clicking here.
Uveitis is the term used to describe inflammation of the middle layer of the eye, which is called the uvea or uveal tract. This may lead to symptoms such as pain in the eye area, vision loss, light sensitivity, and blurred or cloudy vision, amongst other possible features.
Ocular Inflammation Uveitis Treatment
According to UNT’s article, ocular inflammation uveitis can often be treated using corticosteroids, preventing blindness and eye damage. However, Dr Chavala from the North Texas Eye Research Institute says that, while this method may effectively treat inflammation and prevent blindness, over time patients may become intolerant to them, and some oral steroids have a risk of side effects such as hypertension, osteoporosis, and glucose intolerance. Treatment with intraocular steroids, the article says, may minimise these side effects – but comes with a risk of vision loss from cataracts or glaucoma. New treatments are needed to overcome these problems, and researchers are hopeful that MDM2 inhibitor drugs may be a promising route for further research.
Research into MDM2 Inhibitors
Some research suggests that MDM2 inhibitors, which are being investigated for their potential use for cancers, may also be able to reduce ocular inflammation, and this conclusion was supported by studies in mice. The researchers are now keen for further research to be carried out based on these promising early findings.